Bausch + Lomb, a global eye health leader, is facing turbulence after two key board members resigned and the company’s agreement with billionaire investor Carl Icahn was terminated.

Bausch + Lomb Corporation reported strong Q2 2025 results, with revenue growth of 5% and adjusted EBITDA of $191 million, despite facing a product recall.